Clinical trial
An Expanded Access Program for Risdiplam in Patients With Type 1 or Type 2 Spinal Muscular Atrophy
NCT04256265 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Expanded Access Program for Risdiplam in Patients With Type 1 or Type 2 Spinal Muscular Atrophy
- Lead sponsor
- Genentech, Inc.
- Phase
- Expanded access
- Overall status
- Approved for marketing
- Start date
- Not reported
- Completion date
- Not reported
- Enrollment
- Not reported
- Sites
- 29
Conditions
As the registry lists them; a condition with its own page is linked.